Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and ...

Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on LCTX stock, giving a Buy rating on January 3.Stay Ahead of the ...

Shares of Sana Biotechnology surged after the company released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The stock more than tripled, up 265% ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

During islet development, beta-cell death, rather than proliferation alone, regulates beta-cell mass and shapes the immune ...

Medically reviewed by Qin Rao, MD The pancreas is an organ behind the stomach and near the spleen. It performs both exocrine ...

Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...

The clinical data are highly promising for patients and provide the first evidence in humans for overcoming allogeneic and autoimmune rejection with pancreatic islet cell transplantation in type 1 ...